Cost-effectiveness of introducing the pneumococcal conjugate vaccine for children under 5 years in the Islamic Republic of Iran.

BACKGROUND: Pneumococcal disease caused by Streptococcus pneumoniae results in considerable mortality and morbidity. Pneumococcal conjugate vaccines (PCV), such as PCV-13, can prevent invasive pneumococcal disease and avoid disability and death. The cost of introducing PCV-13 in childhood immunization schedules should be assessed against the cost of pneumococcal diseases for each community. AIMS: This study aimed to evaluate the cost-effectiveness of introducing PCV-13 in the national immunization programme for children under 5 years in the Islamic Republic of Iran. METHODS: The TRIVAC decision support model was used to estimate total costs of introducing PCV-13 and the disability- adjusted life years (DALYs) averted. The main pneumococcal diseases were considered-pneumonia, meningitis, acute otitis media, and non-pneumonia, non-meningitis infections-in terms of hospital admissions, outpatient visits and deaths. Local data were used to estimate costs. RESULTS: Pneumococcal disease is estimated to affect 18 713 211 children under 5 years (519 412 pneumonia, 18 148 116 acute otitis media, 6884 meningitis, and 38 799 non-pneumonia, non-meningitis) in 10 years (2014-2023) without use of the vaccine. Introduction of PCV-13 would prevent 4 900 084 cases of pneumococcal disease (190 849 pneumonia, 4 692 450 acute otitis media, 2529 meningitis, and 14 256 non-pneumonia, non-meningitis). Pneumococcal infection would cause 287 950 hospital admissions and 29 399 deaths; vaccination could avert 105 802 hospital admissions and 9997 deaths. The incremental cost-effectiveness was estimated to be US$ 1890 and US$ 1538 per averted DALY for the government and society respectively. CONCLUSION: According to WHO-recommended thresholds for interpreting cost-effectiveness, introduction of PCV-13 for children under 5 years in the Islamic Republic of Iran would be cost-effective.

An investigation into a measles outbreak in southeast Iran.

In 2009 and 2010, a series of measles outbreaks, involving different age groups, occurred in rural areas of the Chabahar district in southeast Iran. These outbreaks raised questions regarding the effectiveness of immunization programs in these areas. To determine the most important factors leading to these outbreaks, and to determine the effectiveness of the measles vaccination program, the present study analyzed surveillance data and performed a case-control study. The total number of reported cases during the study period was 126. The estimated vaccine effectiveness, based on the adjusted odds ratio of the case-control study, was 74.2% (95% CI, 10.2-92.6). On two occasions, both primary and secondary cases of the outbreaks were vaccinated school children. In total, 42% of all cases were aged above 7 years, and 6.3% were above 20 years. With regard to the important role of schools as the foci of contact between uninfected and infected children, supplementary immunization of children before starting in school could be effective in preventing measles outbreaks. In addition, implementation of supplementary immunization every 5-10 years in older age groups might be effective in preventing future outbreaks.